Immunovant, Inc. - Common Stock (NQ:IMVT)

25.15 +0.31 (+1.25%)

Streaming Delayed Price Updated: 3:47 PM EDT, Apr 1, 2026 Add to My Watchlist

Price and Volume

Volume	454,517
Open	25.13
Bid (Size)	25.15 (200)
Ask (Size)	25.17 (300)
Prev. Close	24.84
Today's Range	25.00 - 25.86
52wk Range	12.72 - 29.25
Shares Outstanding	114,998,871
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Performance

YTD	-2.9%	-2.9%
1 Month	-9.4%	-9.4%
3 Month	-0.8%	-0.8%
6 Month	+56.0%	+56.0%
1 Year	+47.2%	+47.2%

More News

Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗

March 11, 2026

Via The Motley Fool

Immunovant Inc (NASDAQ:IMVT) Reports Q3 FY2026 Results, Beats EPS Estimates and Provides Key Clinical Updates ↗

February 06, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗

March 11, 2026

Via The Motley Fool

Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗

March 11, 2026

Via The Motley Fool

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

Via Finterra

Insights into Immunovant's Upcoming Earnings ↗

November 07, 2025

Via Benzinga

Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗

February 06, 2026

Via The Motley Fool

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗

December 18, 2025

Via The Motley Fool

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗

November 10, 2025

Via Chartmill

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 17, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 12, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Why Immunovant Stock Blasted Higher Today ↗

September 03, 2025

Via The Motley Fool

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

August 27, 2025

From The Schall Law Firm

Via Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

August 13, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Immunovant Posts 34% R&D Jump in Q1 ↗

August 11, 2025

Via The Motley Fool

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

June 20, 2025

Via ACCESS Newswire

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗

May 29, 2025

Via Stocktwits

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

May 21, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 22, 2025

Via Benzinga

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?

Yes, Immunovant, Inc. - Common Stock is publicly traded.

What exchange does Immunovant, Inc. - Common Stock trade on?

Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immunovant, Inc. - Common Stock?

The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market

What is the current price of Immunovant, Inc. - Common Stock?

The current price of Immunovant, Inc. - Common Stock is 25.15

When was Immunovant, Inc. - Common Stock last traded?

The last trade of Immunovant, Inc. - Common Stock was at 04/01/26 03:47 PM ET

What is the market capitalization of Immunovant, Inc. - Common Stock?

The market capitalization of Immunovant, Inc. - Common Stock is 2.89B

How many shares of Immunovant, Inc. - Common Stock are outstanding?

Immunovant, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.